567 related articles for article (PubMed ID: 25982552)
1. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA.
Han L; Tang C; Yin C
Biomaterials; 2015 Aug; 60():42-52. PubMed ID: 25982552
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor efficacies of multifunctional nanocomplexes through knocking down the barriers for siRNA delivery.
Han L; Tang C; Yin C
Biomaterials; 2015 Mar; 44():111-21. PubMed ID: 25617131
[TBL] [Abstract][Full Text] [Related]
3. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
4. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
5. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
6. pH-Responsive Core-Shell Structured Nanoparticles for Triple-Stage Targeted Delivery of Doxorubicin to Tumors.
Han L; Tang C; Yin C
ACS Appl Mater Interfaces; 2016 Sep; 8(36):23498-508. PubMed ID: 27558413
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting nanoparticles with core-crosslinked and pH/redox-bioresponsive properties for enhanced intracellular drug delivery.
Zhao J; Yan C; Chen Z; Liu J; Song H; Wang W; Liu J; Yang N; Zhao Y; Chen L
J Colloid Interface Sci; 2019 Mar; 540():66-77. PubMed ID: 30634060
[TBL] [Abstract][Full Text] [Related]
8. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
[TBL] [Abstract][Full Text] [Related]
9. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
10. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
11. Gold nanoparticle-gated mesoporous silica as redox-triggered drug delivery for chemo-photothermal synergistic therapy.
Yang Y; Lin Y; Di D; Zhang X; Wang D; Zhao Q; Wang S
J Colloid Interface Sci; 2017 Dec; 508():323-331. PubMed ID: 28843922
[TBL] [Abstract][Full Text] [Related]
12. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional envelope-type mesoporous silica nanoparticles for pH-responsive drug delivery and magnetic resonance imaging.
Chen Y; Ai K; Liu J; Sun G; Yin Q; Lu L
Biomaterials; 2015 Aug; 60():111-20. PubMed ID: 25988726
[TBL] [Abstract][Full Text] [Related]
14. Molecular structural transformation regulated dynamic disordering of supramolecular vesicles as pH-responsive drug release systems.
Liu Y; Gao FP; Zhang D; Fan YS; Chen XG; Wang H
J Control Release; 2014 Jan; 173():140-7. PubMed ID: 24188958
[TBL] [Abstract][Full Text] [Related]
15. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
[TBL] [Abstract][Full Text] [Related]
16. A Tailored DNA Nanoplatform for Synergistic RNAi-/Chemotherapy of Multidrug-Resistant Tumors.
Liu J; Song L; Liu S; Zhao S; Jiang Q; Ding B
Angew Chem Int Ed Engl; 2018 Nov; 57(47):15486-15490. PubMed ID: 30288887
[TBL] [Abstract][Full Text] [Related]
17. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
18. Near Infrared-Guided Smart Nanocarriers for MicroRNA-Controlled Release of Doxorubicin/siRNA with Intracellular ATP as Fuel.
Zhang P; Wang C; Zhao J; Xiao A; Shen Q; Li L; Li J; Zhang J; Min Q; Chen J; Chen HY; Zhu JJ
ACS Nano; 2016 Mar; 10(3):3637-47. PubMed ID: 26905935
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy.
Chen W; Yuan Y; Cheng D; Chen J; Wang L; Shuai X
Small; 2014 Jul; 10(13):2678-87. PubMed ID: 24668891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
